The most common adverse events (≥Grade 3) during PD-1 inhibitors plus regorafenib treatment were hand-foot skin reaction (HFSR) (n = 5,12.4%) and thrombocytopenia (n = 2, 6.90%). Here, PDCD1 is linked to Thrombocytopenia.